Federal contractor profile
OSIVAX
UEI M4YDKJJRJYC7CAGE FBDR2
Active
Overview
- Legal name
- OSIVAX
- Registered location
- LYON, FRA
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- Latest award activity
- May 19, 2026
Read company summary
OSIVAX is associated with UEI M4YDKJJRJYC7 and CAGE FBDR2 in public federal records. AcornBids currently links 2 prime awards totaling $20.2M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in Biotechnology (except Nanobiotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Its public SAM.gov registration lists LYON, FRA.
At a glance
Lifetime prime obligations$20.2M
Prime awards2
Awards with future end dates2
Top-agency concentration
Not available
Why this customer concentration
Detailed agency totals are not available in this stored profile.
Largest positive coded-agency total ÷ all positive coded-agency totals × 100
Missing data is shown as unavailable.
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Sep 28, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- OSIVAX
- UEI
- M4YDKJJRJYC7
- CAGE
- FBDR2
- Registered address
- 70 RUE ST JEAN DE DIEU, LYON, 69007, FRA
- Registration status
- Active
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- SAM activation
- Apr 28, 2026
- Initial registration
- Oct 17, 2018
- Entity start
- May 15, 2017
- SAM updated
- Apr 28, 2026
- Registration expires
- Apr 28, 2027
- Fiscal year end
- Dec 31
- Place of incorporation
- FRA
Federal award analysis
Net transaction obligations by federal fiscal period.
Transaction history is not available in the loaded data. Annual funding is not estimated from current award totals.
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75A50125C00008OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS | Department of Health and Human Services | $19.5M | Jul 25, 2025 | Jul 24, 2028 |
| 75A50125C00006OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS… | Department of Health and Human Services | $744.0K | Sep 30, 2025 | Mar 31, 2027 |
Upcoming positioning windows
Modeled recompete windows are estimates, not announced solicitations or guarantees.
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Apr 28, 2026 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Oct 17, 2018 |
| Entity start | May 15, 2017 |
| Industry | Reported size status |
|---|---|
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| ALEXANDRE LE VERT | Government business | Contact method not published | SAM registration | Not available |
| ALEXANDRE LE VERT | Electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
70 awards
53 awards
36 awards
34 awards
30 awards
About OSIVAX
What products and services appear in its federal awards?
Recorded award industries: 541714 — Research and Development in Biotechnology (except Nanobiotechnology).
Recorded products and services: AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH; AN14 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES.
Examples from recent award records:
- OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS
- OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS…
These records describe federal award work, not every company capability. Review the award evidence.
Where is the company registered?
70 RUE ST JEAN DE DIEU, LYON 69007, FRA
Registered location from SAM.gov; award performance locations may differ.
What is its primary registered industry?
541714 — Research and Development in Biotechnology (except Nanobiotechnology).
Primary SAM.gov NAICS classification.
Which federal agencies are represented in its awards?
Department of Health and Human Services.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
No official subaward rows are loaded, so Acorn does not claim known teaming relationships.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit